Last week, a small, publicly held antibiotic biotech, Nabriva, announced that it would wind down its operations. Everyone still there lost their jobs.
Dr. David Schlaes
Here we go again. Entasis Therapeutics has been struggling in the public marketplace.
Former vice president of infectious disease re
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
